A Phase Ⅱ Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine
Conditions: SARS-CoV-2 Infection Interventions: Biological: COVID-19 mRNA Vaccine (ZSVG-02-O); Biological: COVID-19 mRNA Vaccine (ZSVG-02-O); Biological: COVID-19 Vaccine (Vero Cell) ,Inactivated Sponsors: CNBG-Virogin Biotech (Shanghai) Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 2, 2023 Category: Research Source Type: clinical trials
A Phase Ⅱ Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 (COVID-19) Vaccine( ZSVG-02-O)
Conditions: SARS-CoV-2 Infection Interventions: Biological: COVID-19 mRNA Vaccine (ZSVG-02-O); Biological: COVID-19 mRNA Vaccine (ZSVG-02-O); Biological: COVID-19 Vaccine (Vero Cell) ,Inactivated Sponsors: CNBG-Virogin Biotech (Shanghai) Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 2, 2023 Category: Research Source Type: clinical trials
A Phase Ⅰ Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 (COVID-19) Vaccine( ZSVG-02-O)
Conditions: SARS-CoV-2 Infection Interventions: Biological: COVID-19 mRNA Vaccine (ZSVG-02-O); Biological: Placebo; Biological: COVID-19 Vaccine (Vero Cell) ,Inactivated Sponsors: CNBG-Virogin Biotech (Shanghai) Ltd.; Shulan (Hangzhou) Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 2, 2023 Category: Research Source Type: clinical trials
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
Lead formulations evaluated in the Phase 1/2 study demonstrated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains
Safety profile of the mRNA-based combination vaccine candidates consistent with the companies’... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 26, 2023 Category: Pharmaceuticals Source Type: clinical trials
Evaluation of Concordance Between Exhaled Air Test (eBAM-CoV) and RT-PCR to Detect SARS-CoV-2
Conditions: SARS-CoV-2 Infection; COVID-19; Coronavirus Interventions: Device: eBAM Cov Testing Sponsors: Centre Hospitalier Universitaire de N īmes; University of Nimes; brains ' laboratory sas, FRANCE Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 25, 2023 Category: Research Source Type: clinical trials
Effect of Apollo Wearable on Long COVID-19 Symptoms.
Conditions: Post-acute Sequelae of SARS-COV-2 Infection Sponsors: The Board of Medicine; Apollo Neuroscience, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 24, 2023 Category: Research Source Type: clinical trials
Effect of Apollo Wearable on Long COVID Symptoms.
Conditions: Post-acute Sequelae of SARS-COV-2 Infection Sponsors: The Board of Medicine; Apollo Neuroscience, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 24, 2023 Category: Research Source Type: clinical trials
A Study of mRNA-1083 (SARS-Cov-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age
Conditions: SARS-CoV-2; Influenza Interventions: Biological: mRNA-1083; Biological: Placebo; Biological: Influenza Vaccine; Biological: COVID-19 Vaccine Sponsors: ModernaTX, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 24, 2023 Category: Research Source Type: clinical trials
Rural Tailored Communication to Promote SARS-CoV-2 Antibody Testing in Saliva
Conditions: SARS-CoV2 Infection Interventions: Behavioral: General SARS-CoV-2 Communication; Behavioral: Rural-Targeted SARS-CoV-2 Communication Sponsors: Michigan State University; National Cancer Institute (NCI); Johns Hopkins University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 17, 2023 Category: Research Source Type: clinical trials
Long Term Effects of Awake Prone Positioning in COVID-19 ICU Patients
Conditions: SARS-CoV 2 Pneumonia Interventions: Other: quality of life questionnaire Sponsors: University Hospital, Tours Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 12, 2023 Category: Research Source Type: clinical trials
Advanced Modeling of the Evolution of the Epidemiological Outbreak of SARS-CoV-2 Pandemic
Conditions: COVID-19 Sponsors: Hospital Galdakao-Usansolo; Basque Government Department of Public Health; University of the Basque Country (UPV/EHU); BCAM (Basque Center for Applied Mathematics); Osakidetza Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 6, 2023 Category: Research Source Type: clinical trials
Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance
Conditions: Follicular Lymphoma Interventions: Diagnostic Test: Cellular immunity vs SARS-CoV-2; Diagnostic Test: Humoral immunity vs SARS-CoV-2; Diagnostic Test: Cellular immunity vs Varicella Zoster Virus; Diagnostic Test: Humoral immunity vs Varicella Zoster Virus; Diagnostic Test: Diphtheria toxin-binding IgG; Diagnostic Test: Tetanus toxoid-binding IgG; Diagnostic Test: T-cell populations and markers characterization Sponsors: Fondazione Italiana Linfomi - ETS Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 6, 2023 Category: Research Source Type: clinical trials
Bacillus Calmette-Gu érin vaccination as defense against SARS-CoV-2 (BADAS): a randomized controlled trial to protect healthcare workers in the USA by enhanced trained immune responses
DiscussionIt is expected this trial will allow evaluation of the effects of BCG vaccination at a population level in high-risk healthcare individuals through a mitigated clinical course of SARS-CoV-2 infection and inform policy making during the ongoing epidemic.Trial registrationClinicalTrials.gov NCT04348370. Registered on April 16, 2020. (Source: Trials)
Source: Trials - October 4, 2023 Category: Research Source Type: clinical trials
The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection
Conditions: COVID-19; Vaccine-Preventable Diseases; SARS CoV 2 Infection; Upper Respiratory Tract Infection; Upper Respiratory Disease Interventions: Biological: Novavax COVID-19 vaccine (2023-2024 formula XBB containing); Biological: Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing) Sponsors: Sarang K. Yoon, DO, MOH; Westat; Novavax Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 3, 2023 Category: Research Source Type: clinical trials
Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects
Conditions: COVID-19; Infectious Disease; Symptomatic COVID-19 Infection Laboratory-Confirmed; SARS CoV 2 Infection Interventions: Combination Product: RQ-001; Other: Placebo Sponsors: Red Queen Therapeutics, Inc.; PPD Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 2, 2023 Category: Research Source Type: clinical trials
